Neurotech International Ltd (ASX:NTI) Share Price

Company Profile

Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUS
T: +61 394983132
https://www.neurotechinternational.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18

Recommended

With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.

Dan Romanoff, CPA | 08 May 2026

Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.

Seth Goldstein, CFA | 08 May 2026

With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.

Jacob Robbins | 08 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,980.50	31.60	-0.35%
CAC 40	8,112.57	89.51	-1.09%
DAX 40	24,338.63	324.98	-1.32%
Dow JONES (US)	49,608.09	11.12	0.02%
FTSE 100	10,233.07	43.88	-0.43%
HKSE	26,393.71	232.57	-0.87%
NASDAQ	26,177.74	371.55	1.44%
Nikkei 225	62,713.65	120.19	-0.19%
NZX 50 Index	13,175.13	95.48	-0.72%
S&P 500	7,397.03	59.92	0.82%
S&P/ASX 200	8,744.40	36.40	-0.41%
SSE Composite Index	4,179.95	0.14	-0.00%